Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II study of TB001 injection plus tenofovir alafenamide for chronic hepatitis B liver fibrosis
CTR20241825Phase 2Active
- Sponsor
- T-Win Biotech
- Start
- May 2024
- Modality
- Small Molecules, Peptides
- Countries
- 1
01
Overview
A Phase 2 trial of tb001, tenofovir alafenamide in Chronic Hepatitis B (CHB), hepatic fibrosis, sponsored by T-Win Biotech. Started May 2024; status: active.
02
Drugs
tb001tenofovir alafenamide
03
Conditions
Chronic Hepatitis B (CHB)hepatic fibrosis
Beyond the preview
Go deeper on CTR20241825.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20241825.